hat
Halotestin se anpil afekte pa anzim redaktaz la 5-Alpha, menm anzim la ki responsab pou rediksyon nan testostewòn dihydrotestosterone. Pou rezon sa a, itilize nan yon inhibitor redaktaz 5-alpha tankou Finasteride ka diminye efè segondè ki gen rapò ak Androjenik nan Halotestin. Itilizasyon sa yo pa pral konplètman anba men aktivite Androjenik esteroyid sa a, men li te kapab redwi li. Sepandan, moun ki fòtman siseptib nan efè segondè Androjenik pral pwobableman bezwen abandone sa a itilize esteroyid la.
eng
Halotestin is greatly affected by the 5-alpha reductase enzyme, the same enzyme responsible for the reduction of testosterone to dihydrotestosterone. For this reason, the use of a 5-alpha reductase inhibitor such as Finasteride may reduce the related androgenic side effects of Halotestin. Such use will not completely subdue this steroid’s androgenic activity, but it could potentially reduce it. However, those who are strongly susceptible to androgenic side effects will probably need to forgo this steroid’s use.